Semi-solid phase assay for the alternative complement pathway activity assessment (AP₁₀₀)

References

• Ricklin, D.; Hajishengallis, G. Yang K, Lambris JD. Complement: A Key System for Immune Surveillance and Homeostasis. Nat. Immunol. Sep 2010, 11(9), 785–797.
   PubMed Web of Science ®Google Scholar
• Shih, A. R.; Murali, M. R. Laboratory Tests for Disorders of Complement and Complement Regulatory Proteins. Am. J. Hematol. 2015, 1180. doi:10.1002/ajh.24209.
   PubMed Web of Science ®Google Scholar
• Holers, V. M.;. The Spectrum of Complement Alternative Pathway-mediated Diseases. Immunol. Rev. 2008, 223, 300–316. DOI: 10.1111/j.1600-065X.2008.00641.x.
   PubMed Web of Science ®Google Scholar
• Kerboua, K.; Haiba, F.; Batouche, D. C3: CH50ratio as a Proposed Composite Marker for Eculizumab Monitoring in Atypical Hemolytic Uremic Syndrome: Preliminary Results. J. Immunoassay Immunochem. 2017, 38(2), 178–189.
   PubMedGoogle Scholar
• Angioi, A.; Fernando, C.; Fervenza, S. S.; Yuzhou, Z.; Smith, R. J.; Murray, D.; Van Praet, J.; Pani, A.; De Vriese, A. S. Diagnosis of Complement Alternative Pathway Disorders. Kidney Int. 2016, 89(2), 278–288. DOI: 10.1016/j.kint.2015.12.003.
   PubMed Web of Science ®Google Scholar
• Song, D.; Guo, W. Y.; Wang, F. M.; Li, Y. Z.; Song, Y.; Yu, F.; Zhao, M. H. Complement Alternative Pathway׳s Activation in Patients with Lupus Nephritis. Am. J. Med. Sci. 2017, 353(3), 247–257. DOI: 10.1016/j.amjms.2017.01.005.
   PubMed Web of Science ®Google Scholar
• Lindorfer, M. A.; Pawluczkowycz, A. W.; Peek, E. M.; Hickman, K.; Taylor, R. P.; Parker, C. J. A Novel Approach to Preventing the Hemolysis of Paroxysmal Nocturnal Hemoglobinuria: Both Complement-mediated Cytolysis and C3 Deposition are Blocked by A Monoclonal Antibody Specific for the Alternative Pathway of Complement. 18. Blood.2010, 115(11), 2283–2289. DOI: 10.1182/blood-2009-09-244285.
   PubMed Web of Science ®Google Scholar
• Lewis, L. A.; Ram, S. Meningococcal Disease and the Complement System. Virulence. 2014, 5(1), 98–126. DOI: 10.4161/viru.26515.
   PubMed Web of Science ®Google Scholar
• Rodríguez‐Sanz, A.; Sánchez‐Villanueva, R.; Domínguez‐Ortega, J.; Fiandor, A.; Ruiz, M.; Trocoli, F.; Díaz‐Tejeiro, R.; Cadenillas, C.; González, E.; Martínez, V.; et al. Mechanisms Involved in Hypersensitivity Reactions to Polysulfone Hemodialysis Membranes. Artif. Organs. 2017. DOI: 10.1111/aor.12954.
   PubMed Web of Science ®Google Scholar
• Markiewski, M. M.; DeAngelis, R. A.; Lambris, J. D. Complexity of Complement Activation in Sepsis. J. Cell Mol. Med. 2008, Dec; 12(6a), 2245–2254. DOI: 10.1111/j.1582-4934.2008.00504.x.
   PubMed Web of Science ®Google Scholar
• Pangburn, M. K.;. The Alternative Pathway. In Immunobiology of the Complement System; Ross, G., Ed.; Academic Press: San Diego, 1981; pp 45–62.
   Google Scholar
• Pangburn, M. K.;. Alternative Pathway of Complement. Methods Enzymol. 1988, 162, 648–649.
   Web of Science ®Google Scholar
• Thomas, A. E.;. Platts-Mills and Kimishige Ishizaka; Activation of the Alternate Pathway of Human Complement by Rabbit Cells. J. Immunol. July 1, 1974, 113(1), 348–358.
   PubMed Web of Science ®Google Scholar
• Servais, G. 1.; Walmagh, J.; Duchateau, J. Simple Quantitative Haemolytic Microassay for Determination of Complement Alternative Pathway Activation (AP50). J. Immunol. Methods. Jun 1991, 140(1), 93–100. DOI: 10.1016/0022-1759(91)90130-8.
   PubMed Web of Science ®Google Scholar
• Kazatchkine, M.; Hauptmann, G.; Nydegger, U. Dosage De L’activité Fonctionnelle De La Voie Alterne VAH50. Techniques En Immunologic. In Techniques Du Complement; INSERM collection technique en immunologie (Ed.) . 1985, Inserm: Paris; 34.
   Google Scholar
• Kazatchkine, M. D.; Nydegge, U. E. The Human Alternative Complement Pathway: Biology and Immuno- Pathology of Activation and Regulation. Proc. Allergy. 1982, 130, 193.
   Google Scholar
• Puissant-Lubrano, B.; Puissochet, S.; Congy-Jolivet, N.; Chauveau, D.; Decramer, S.; Garnier, A.; Huart, A.; Kamar, N.; Ribes, D.; Blancher, A. Alternative Complement Pathway Hemolytic Assays Reveal Incomplete Complement Blockade in Patients Treated with Eculizumab. Clin. Immunol. Oct, 2017, 183, 1–7. DOI: 10.1016/j.clim.2017.06.007.
   PubMed Web of Science ®Google Scholar